Navigation Links
Edison expands international bio-pharmaceutical presence with launch of coverage of Onconova Therapeutics
Date:11/19/2013

LONDON, Nov. 19, 2013 /PRNewswire/ -- Edison Investment Research, a leading international investment research firm, announces the launch of full coverage of Onconova Therapeutics, a NASDAQ-listed clinical-stage bio-pharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer.Edison's comprehensive report, ONTIME to deliver, was published on 15 October and examines the investment case for the development of rigosertib (IV). The report highlights that if rigosertib (IV) meets its primary endpoint in the ONTIME Phase III trial in higher-risk, second-line MDS in Q114, Onconova could be in a position to file its first NDA next year.

The analysis by Edison's healthcare team indicates this would represent something to which few recent IPO companies could aspire. Oral rigosertib, which is in Phase II trials for lower-risk MDS, could open a much larger market if positive Phase II data are confirmed in a pivotal trial. With three drug candidates in clinical trials, six active preclinical programmes and cash beyond 2014, Onconova appears to be an attractive investment. We value the company at $476m, or $22.3/share.

For the full report see: www.edisoninvestmentresearch.com/research/company/onconova-therapeutics

The launch of coverage on Onconova Therapeutics is part of a programme of research initiations on bio-pharmaceutical companies exposed to global market opportunities. Edison provides detailed research coverage on more than 150 pharmaceutical and healthcare companies in Europe, North America, Australia and New Zealand. Its healthcare research team has a range of coverage across small-, mid- and large-cap companies. All reports published by Edison are available to download free of charge from its website www.edisongroup.com.

About Edison Investment Research Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals works with leading companies, fund managers and investment banks worldwide to support its capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584).

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities. For more information please contact:Jason ZhangEdison Investment Research+1 646 653 7027healthcare@edisongroup.comAbout Onconova TherapeuticsOnconova Therapeutics is a clinical-stage bio-pharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. Using a proprietary chemistry platform, it has created an extensive library of targeted anti-cancer agents.


'/>"/>
SOURCE Edison Investment Research
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Diabecline Antibiotic Receives Edison Award for Best New Pharmaceutical Product
2. Carolinas HealthCare System and Edison Nation Collaborate to Drive Medical Innovation and Technology
3. EMA Grants Orphan Designation to Edison Pharmaceuticals for EPI-743 for Treatment of Leigh Syndrome
4. Edison Pharmaceuticals Announces Positive Results of EPI-743 Phase 2A Leigh Syndrome Clinical Trial
5. Massive Hiring Event for Life Science Professionals in Edison, NJ on 9/18/12
6. Edison Pharmaceuticals Announces Initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
7. Edison Pharmaceuticals Closes $20M Series F Financing
8. Samsung Medison Showcases New Medical Equipment and Technology with Samsung Electronics at RSNA 2012
9. Edison Pharmaceuticals & Bambino Gesu Childrens Hospital Announce Initiation of EPI-743 Phase 2 Cobalamin C Deficiency Syndrome Clinical Trial
10. Edison Pharmaceuticals, Inc. signs licensing agreement with Dainippon Sumitomo Pharma Co., Ltd. for development & commercialization of orphan mitochondrial and adult central nervous system disease drugs
11. Edison Expands North American Healthcare Sector Coverage With Initiation of Coverage on Bellus Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 2017 Research and Markets has announced the ... - 2016" report to their offering. ... The latest research Urinary Incontinence Drugs ... benchmarks in the global Urinary Incontinence market. The research answers ... key drugs marketed for Urinary Incontinence and their clinical attributes? How ...
(Date:2/23/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The latest research Autism Spectrum Disorder Drugs Price Analysis ... the global Autism Spectrum Disorder market. The research answers the ... drugs marketed for Autism Spectrum Disorder and their clinical attributes? How ...
(Date:2/23/2017)... , Südkorea, 23. Februar 2017 LG ... für Sterilisationsaufgaben vorgestellt. Die Sterilisationsleistung beträgt das 1,5-fache des ... ultraviolette Strahlung im Bereich zwischen 200 und 280 nm und ... von Bakterien, indem es ihre DNA zerstört. Das Produkt ... ...
Breaking Medicine Technology:
(Date:2/24/2017)... Australia (PRWEB) , ... February 24, 2017 , ... The ... AU) offers Erik Schanssema ’s true account of his paramedic experiences. Schanssema describes ... stress disorder and his attempts to overcome them. , Schanssema, initially unsure of ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... Yisrayl Hawkins, ... focuses on Bible Prophecy concerning this present generation. Yisrayl makes an astounding statement ... current generation. He explains that the Bible details the current times so plainly ...
(Date:2/24/2017)... ... 24, 2017 , ... The Radiology Business Management Association will select ... the annual Building Better Radiology Marketing Programs conference, held this year from ... Texas. Nine awards are given out in five categories. They are:, ...
(Date:2/24/2017)... ... 2017 , ... Castle Farms, the celebrated Northern Michigan ... the winning couple announced on Feb. 14, 2017, on Facebook. The free wedding ... A Matter of Taste, Ryan Rousseau Enterprises, A Touch of Spring and Other ...
(Date:2/23/2017)... , ... February 23, 2017 , ... The 89th Academy ... winner of the 2016 National Education Policy Center Bunkum Award. We invite you to ... 2016. , This year’s Bunkum winner is the Center for American Progress (CAP), for ...
Breaking Medicine News(10 mins):